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Abstract.  The control of smooth muscle cell (SMC) 
proliferation is determined by the combined actions of 
mitogens, such as platelet-derived growth factor, and 
the opposing action of growth inhibitory agents, such 
as heparin and transforming growth factor-/~ (TGF-B). 
The present studies identify an interaction between 
heparin and TGF-3 in which heparin potentiates the 
biological action of TGF-B.  Using a neutralizing anti- 
body to TGF-3, we observed that the short term an- 
tiproliferative effect of heparin depended upon the 
presence of biologically active TGF-3.  This effect was 
observed in rat and bovine aortic SMC and in CCL64 
cells, but not in human saphenous vein SMC. Binding 
studies demonstrated that the addition of heparin (100 
/~g/ml) to medium containing 10%  plasma-derived se- 
rum resulted in a 45 % increase in the specific binding 
of ~5I-TGF-3 to cells. Likewise, heparin induced a 
twofold increase in the growth inhibitory action of 
TGF-3 at concentrations of TGF-3 near its apparent 
dissociation constant. Using '25I-labeled TGF-B,  we 
demonstrated that TGF-B complexes with the plasma 
component uz-macroglobulin, but not with fibronectin. 
Heparin increases the electrophoretic mobility of TGF- 
3  apparently by freeing TGF-3 from its complex with 
u2-macroglobulin. Dextran sulfate, another highly 
charged antiproliferative molecule, but not chondroitin 
sulfate or dermatan sulfate, similarly modified TGF-3's 
mobility. Relatively high, antiproliferative concentra- 
tions of heparin (1-100 #g/ml) were required to dis- 
sociate the TGF-3/ot2-macroglobulin complex. Thus, it 
appears that the antiproliferative effect of heparin may 
be partially attributed to its ability to potentiate the bi- 
ological activity of TGF-3 by dissociating it from 
t~2-macroglobulin,  which normally renders it inactive. 
We suggest that heparin-like agents may be important 
regulators of TGF-3's biological activity. 
HEROSCLEROSIS is characterized both by proliferative 
changes in the arterial cells and by biochemical alter- 
ations  in the extracellular matrix that lead to local 
occlusive and thrombotic complications.  The intimal inva- 
sion  and  proliferation  of  vascular  smooth  muscle  cells 
(SMCs)' may be a key step in the pathogenesis  of athero- 
sclerosis (51). After arterial injury, humans and a variety of 
other species develop a neointimal vascular lesion composed 
partially of cells expressing SMC antigens (50, 62).  In ex- 
perimental animals,  formation of arteriosclerotic lesions is 
inhibited by heparin pretreatment (8, 17). This effect of hepa- 
rin correlates with its ability to inhibit arterial SMC growth 
in vitro  (4,  12,  21,  41,  47),  and is  distinct  from its  an- 
ticoagulant  action (17, 33).  The proliferation  of other cell 
types such as fibroblasts,  skeletal muscle cells,  and tumor 
cell lines is also inhibited by heparin (10, 24, 28, 33). 
The antiproliferative effect of  heparin may be of physiolog- 
1. Abbreviations used in this paper: o~2-M, ot2-macroglobulin; CPC, cetyl- 
pyridium  chloride;  ITS,  iasulin-transferrin-selenium; PDS,  plasma-de- 
rived bovine serum; SMC, smooth muscle cell; TGF-3, transforming growth 
factor beta. 
ical significance because endothelial cells and postconfluent 
SMCs produce heparan sulfate proteoglycans that act simi- 
larly to heparin (16, 28). Likewise, highly sulfated polysac- 
charides such as dextran sulfate and mactin can also have 
antiproliferative effects (33). Other cell-derived glycosamino- 
glycans, such as chondroitin sulfate and dermatan sulfate, do 
not exert antiproliferative effects. We have previously reported 
that heparin corrects the excessive proliferation of SMC de- 
rived from aged rats (38). We subsequently observed, as did 
others (1), that transforming growth factor type beta (TGF-3) 
was also  a potent  inhibitor  of SMC  monolayer growth in 
vitro.  The inhibition  induced by TGF-/3, however, was ob- 
served at almost a 1,000-fold lower molar concentration than 
has been reported for heparin. To study the mechanism of 
heparin's  antiproliferative  effect, we tested  the hypothesis 
that heparin inhibited SMC proliferation  by stimulation of 
TGF-3 activity. Even though TGF-B has not been regarded 
as a heparin-binding growth factor, our findings demonstrate 
a significant and specific biological interaction between hep- 
arin and TGF-3 that could contribute to the antiproliferative 
effect of heparin on vascular SMC as well as other cell types. 
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Reagents 
Human TGF-~ (type 1) and PDGF (>99% pure)  were purchased from R 
& D Systems (Minneapolis, MN). FBS was from Flow Laboratories,  Inc. 
(McLean, VA) and plasma-derived bovine serum (PDS) was from Biomedi- 
cal Technologies,  Inc.  (Cambridge, MA). Tritiated  thymidine (1 mCi/ml; 
New England Nuclear,  Boston, MA) was used for proliferation  assays, c~2- 
Macroglobulin (c~2-M) was kindly provided by Dr.  Peter Harpel (Cornell 
University Medical College, New York). Fibronectin was isolated from hu- 
man serum by published techniques (14). Sodium heparin, dermatan sulfate, 
and dextran sulfate were purchased from Sigma Chemical Co.  (St. Louis, 
MO). Chondroitin-6-sulfate  was acquired from the Seikagaku  KOgyo Co. 
(Tokyo, Japan) through Miles Laboratories (Naperville, IL). Heparin of low 
anticoagulant activity (RD'/; 7  U/rag) was kindly provided by the Hepar 
Corp. (Chicago, IL). A highly charged beparin species was recovered from 
commercially available beparin (Sigma Chemical Co.) by precipitation with 
cationic cctylpyridium chloride (CPC).  The beparin-CPC complex  was 
partially dissolved  with 1.6 M NaCI/0.05 M CPC. Complexes  resistant to 
1.6 M NaCI were recovered  and dissolved  in 2 M  NaCI/absolute  ethanol 
(100:15, voi/vol). This heparin fraction (Hepl.6) was purified by several cy- 
cles of ethanol precipitation.  Unless otherwise specified,  heparin used in 
these experiments is commercially available  Sigma beparin. 
Cell Culture 
Aortic SMCs were obtained from several sources. Bovine aortic SMCs iso- 
lated from explants of fresh bovine aortic media were kindly provided by 
Drs. David Hajjar and Andrew Nieholson (Cornell University Medical Col- 
lege). Rat aortic SMCs were isolated by explant from male Fisher 344 rats 
that had undergone balloon catheter-induced aortic deendothelialization  2 
wk previously  (40, 58).  Human saphenous vein SMCs were isolated from 
explanted medial segments of  vein segments remaining after coronary artery 
bypass  and obtained in accordance with Institutional Review Board ap- 
proved protocols. Cultured cells were confirmed as SMCs by positive stain- 
ing for the smooth muscle-specific isoform of actin as recognized  by the 
monocional antibody HHF35 (kindly provided by Dr. Allen Gown, Univer- 
sity of Washington, Seattle, WA). Cultures of SMCs were used in the second 
to sixth subpassage. Mink lung epithelial cells (CCL64) were obtained from 
the American Type Culture Collection (Rockville, MD) in the 60th passage 
and used in passages 62-68. All cell cultures were maintained in medium 
199 (Gibeo Laboratories,  Grand Island, NY) supplemented  with 10% FBS 
and 50 p.g/ml gentamicin sulfate  (Gibco Laboratories). Subpassage  was 
achieved  with trypsin/EDTA  (Flow Laboratories) and a 3:1 split ratio. 
crotiter  wells,  using  a  previously  published  method  developed  by  the 
authors (37). 
Binding Studies 
Binding studies were performed essentially as described by Ruff and Riz- 
zino (52).  CCL64 cells were plated  in normal growth medium in 24-well 
Costar (Cambridge,  MA) plates at a density of 50,000 cells per well for 48 h. 
The cells were then washed twice with binding buffer (medium 199 plus 
0.1% BSA) and iodinated  TGF-/3 was applied  to the cells in medium 199 
plus 10% PDS. All binding studies were performed after preequilibration of 
the cells and medium in a 4°C cold room and during gentle agitation on 
a  rotary  shaker.  Nonspecific  binding was assessed  by adding 100 ng/ml 
(>100-fold excess) unlabeled crude TGF-/3 (20% pure; R & D Systems) at 
the time the iodinated  ligand was added. 2 h later,  the cells were washed 
three times with ice cold binding medium and bound radioactivity  was ex- 
tracted by treating the cells with lysing medium (PBS plus 0.1% Triton X-100 
and 10% glycerol).  Previous studies have established that this method ex- 
tracts a  large  percentage  of the cell-bound ligand  without releasing  the 
nonspecifically  bound counts (52). 
Agarose Gel Electrophoresis 
The effect of heparin on the electrophoretic mobility of ~25I-TGF-~ was 
analyzed by electrophoresis in uncharged, 1% composite agarose-galacto- 
mannan gels (Isogel; FMC Bioproducts  Corp., Rockland,  ME). Gels pre- 
pared with 50 mM Tris-acetate  buffer (pH 7.0) were run at 150 V/20 mA 
for ,~4 h with cooling. After electrophoresis,  sample wells were filled with 
molten agarose and allowed to cool to prevent the loss of unmigrated TGF-fl. 
Proteins were fixed in 10% trichloroacetic acid for 1 h and then washed free 
of acid and buffer overnight in water. After drying, gels were stained with 
0.1% Coomassie brilliant blue R  in water/ethanol/acetic  acid (65:25:10, 
vol/vol/vol),  then destained, and exposed  overnight to Kodak XAR film 
(Eastman Kodak Co., Rochester, NY) above a Cronex Lightning Plus inten- 
sifying screen. 
Results 
Proliferation Assays 
The inhibitory effect of heparin on SMC proliferation, and the contribution 
of TGF-~ to that activity,  was evaluated  by a short term assay of tritiated 
thymidine incorporation into DNA. This design was used to minimize the 
possible contributions of any cell-derived inhibitors.  SMCs were  plated in  3oo~oo  - 
normal culture medium at 10,000 cells/well in 96-well microtiter plates. Af- 
ter 48 h, the cells were washed once with plain medium 199 and then ex- 
posed to the test medium for 14 h before addition of tritiated thymidine (1 
/~Ci/well) for 4 h before harvest. Incorporation of radiolabeled  thymidine 
into DNA was measured by published methods (38). Reported values reflect  2oo~oo 
the average of six replicate wells per experiment. Inhibition of TGF-/~ activ-  t~ 
ity by specific antibody was achieved by preincubating the test medium for 
1 h with a  1:10 dilution of a 1 mg/ml solution of rabbit anti-human TGF-3 
(R & D Systems) known to neutralize the biological  activity of •2  ng/ml  lOOp00 . 
TGF-/3 (25).  Control groups were incubated with an identical  dilution of 
nonimmune rabbit IgG. 
l odinatio  n of TG  F-~ 
TGF-/~ was iodinated by minor modifications  of the chloramine-T  method 
of RUff  and Rizzino (52). Radiolabeled protein normally exhibited a specific 
activity of 2.5 x  IO  s cpm/ag protein and migrated as a single DTT-reduc- 
ible hand on SDS-PAGE. Comparison of radiolabeled and unlabeled protein 
in a growth inhibition assay using CCL64 fibroblasts  indicated  equivalent 
biological  activities.  Inhibition of growth in these studies was determined 
either by cell counts on a ZBI counter (Coulter Electronics Inc., Hialeah, 
FL) or by determining DNA content per well by a fluorometric assay in mi- 
Serum Dependence of the A n  U'proliferative Effect 
of Heparin 
The antiproliferative effect of heparin on SMCs has been ob- 
served under culture conditions that included serum  (48). 
We had previously observed that the proliferation of SMCs 
derived from young (3-4-mo) rats cultured in 2 % PDS and 
stimulated with PDGF was not inhibited by heparin (38). To 
0~ 
2%  PDS  +PDGF  +  HEP  10%  FBS  +  HEP 
Figure  1.  Serum dependence of heparin's antiproliferative effect. 
Rat aortic SMC were plated in 10% FBS 48 h before exposure to 
the following culture conditions.  18 h  after exposure to 2% PDS, 
2% PDS  +  10 ng/ml PDGF, PDGF  +  heparin (100/~g/ml),  10% 
FBS, or 10% FBS  +  heparin, the cells were pulsed with tritiated 
thymidine (1  ~Ci/well) for 2  h.  The data points are the mean  + 
SEM of six replicate wells. 
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Figure 2. Reversibility of heparin-induced inhibition by antibody to  ~.°~ 
TGF-/L (A) Bovine aortic SMC, (B) rat aortic SMC, and (C) human 
saphenous vein SMC cells were plated in normal culture medium 
48  h before  the  experiment.  The medium  was then changed  to 
medium plus 5 % FBS with (hatched bars) or without (solid bars) 
addition of heparin (100 tzg/ml) for 18 h before exposure to a 4-h 
pulse of tritiated  thymidine.  In the  specified groups,  antibody to  =~ 
TGF-B or  nonimmune  rabbit  IgG was  added  at  100  ,g/ml  to  ® 
medium plus 5 % FBS  1 h previous to adding this to cells.  Data 
points are the mean +  SEM of six replicate wells. 
compare the inhibitory effect of heparin on the proliferation 
of cells stimulated with serum to the effect of heparin on cells 
stimulated with PDGF, rat SMCs were changed from normal 
culture medium to either 2% PDS plus PDGF (10 ng/ml) and 
insulin-transferrin-selenium (ITS; Sigma Chemical Co.) or 
to 10% FBS plus ITS. Parallel groups of cells in both media 
were also treated with heparin (100/~g/ml) for 18 h before 
a  2-h  exposure to  tritiated  thymidine.  As  Fig.  1 demon- 
strates, the PDGF-stimulated rate of DNA synthesis in media 
containing 2 % PDS is not altered by heparin. Whole blood 
serum-stimulated (10%  FBS)  DNA synthesis, however,  is 
strongly  suppressed by heparin to approximately the level 
observed with PDGF stimulation. The initial levels of stimu- 
lated DNA synthesis differ between the PDGF- and serum- 
stimulated  groups.  Nonetheless,  the  PDGF-treated  cells 
show stimulated DNA synthesis which was not inhibited by 
heparin to the level of the 2%  PDS control. 
The Effects of  Antibody to TGF-f3 
on the Growth of SMCs 
In parallel studies using rat SMC cultures grown in 2 % PDS, 
it was observed that a neutralizing titer of antibody to TGF-/~ 
(100/~g/ml) caused a 36% increase in the rate of DNA syn- 
thesis  above control  (control  =  4,576  5:356  @m/well; 
anti-TGF-/3 =  6,206  5:482 dpm/well; mean 5- SEM, n  = 
10).  In the complete absence of PDS or FBS in the culture 
media, anti-TGF-/3 essentially doubled the rate of thymidine 
incorporation (medium 199 +  ITS =  12,367.4 +  902.3 dpm/ 
well vs. antibody-treated wells  =  23,265.2  +  2,183.9 dpm/ 
well, n  =  5).  Nonimmune IgG has no effect on the rate of 
thymidine incorporation in these cells (Fig. 2). Because this 
antibody-stimulated DNA  synthesis  was observed in ceils 
that were presumably devoid of exogenous TGF-~, it suggests 
that these rat SMCs were producing TGF-~ which was in- 
hibiting their own growth in an autocrine fashion. The con- 
tribution of serum- and cell-derived TGF-/~ to heparin's an- 
tiproliferative effect was examined in the following study. 
Reversal of Heparin Inhibition by Antibody to TGF-f3 
The apparent dependence of heparin's antiproliferative effect 
on a serum component suggests the possible involvement of 
a platelet-derived substance, such as TGF-/3, that is present 
in whole blood serum but not in plasma-derived serum. To 
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Figure 3. Effects of heparin on the binding of I251-TGF-~. CCL64 
cells were plated in normal culture medium 48 h before the experi- 
ment at a density of 25,000 ceUs/weU of a 24-well plate. Binding 
of 0.1  ng/well (25,000 cpm) IzsI-'I'GF-~  was assessed in the pres- 
ence (nonspecific) or absence (total) of a >100-fold excess of unla- 
beled TGF-tL Data points represent the mean of quadruplicate de- 
terminations  in  each  of three  replicate  experiments.  The cpm's 
corresponding  to the  100% value for each measure of binding are 
total = 621.2 :l: 110 (SEM), nonspecific = 295.8 + 95, and specific 
=  325.3 5: 39. Asterisks indicate control (solid bars) and heparin 
(hatched bars) groups are significantly different, P < 0.05. 
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Figure 4. Effects of heparin on the antiproliferative action of TGF- 
/~. CCL64 cells were plated at 10,000 cells per microtiter well in 
normal  culture  medium 48  h  before use. The cells  were  then 
changed to medium plus 5 % PDS and increasing doses of TGF-# 
with (dashed line) or without (solid  line) 100 #g/ml heparin for 18 h 
before exposure to a 4-h pulse of tritiated thymidine. Each point 
represents the mean + SEM, n = 6; asterisks indicate that control 
and heparin groups are significantly different, P < 0.01. 
test the hypothesis that heparin potentiates TGF-~ activity 
present in serum, or produced by the SMCs themselves, we 
examined the ability of heparin to inhibit proliferation in the 
presence or absence of  an antibody known to neutralize TGF- 
/i As demonstrated in Fig. 2, heparin was an effective  growth 
inhibitor for bovine SMCs (Fig. 2A), rat SMCs (Fig. 2B), 
and human saphenous vein SMCs (Fig. 2 C). In both the bo- 
vine and rat arterial SMC cultures, however, heparin did not 
inhibit DNA synthesis when the culture was pretreated with 
antibody to TGF-/i Similar results were obtained even when 
CCL64 were used as target cells (data not shown). Further- 
more,  in  the  presence  of anti-TGF-~  DNA  synthesis  by 
SMCs was stimulated,  suggesting that the concentration of 
TGF-~ present in medium containing 5 % FBS was inhibitory 
to proliferation. Heparin also inhibited the growth of saphe- 
nous vein SMCs, but in these cells the inhibitory effect per- 
sisted in the presence of  antibody to TGF-~, suggesting either 
incomplete neutralization of the TGF-~, or a second pathway 
for the inhibitory effect of heparin. However, the prolifera- 
tion of the saphenous vein SMCs was not inhibited by TGF-~ 
as determined not only by the absence of an antibody effect, 
but also by treating replicate wells directly with TGF-~/(data 
not shown).  Yet, in three of the four cell strains tested, the 
inhibitory  action  of heparin  was  blocked  by  antibody  to 
TGF-~. 
Effects of  Heparin on the Binding of TGF-B 
Having demonstrated that heparin loses its short term an- 
tiproliferative effect in  the  absence  of biologically active 
TGF-/$, we addressed the possibility that heparin potentiates 
the activity of TGF-/~ by increasing the specific binding of 
TGF-~ to cells. This possibility was examined by determin- 
ing if heparin altered specific binding of radiolabeled TGF-~ 
to cells under conditions similar to those of the growth inhi- 
bition assay.  We chose CCL64 cells for this assay because 
of their sensitivity to the antiproliferative action of TGF-13 
and their ease of handling. Scatchard analysis of the binding 
of radiolabeled TGF-~ to CCL64 cells indicated the presence 
of a very high affinity,  low capacity binding site with an ap- 
parent K~ of 8.3 pM (not shown). We chose a subsaturating 
concentration of TGF-~ (9.8 pM, 25,000 cpm/well), near the 
apparent  dissociation  constant,  to  examine  the  effects of 
heparin on TGF-/3 binding. 
To approximate cell culture conditions, the binding studies 
were conducted in the presence of 10% PDS with or without 
the addition of heparin  (100  #g/ml).  Whole blood  serum 
could not be used in these studies because of  the confounding 
effects of unlabeled serum TGF-/i Preliminary experiments 
(not shown) indicated that the presence of 10% PDS or 100 
#g/ml  of c~2-M reduced both total and  specific binding of 
'25I-TGF-~/ to these cells,  consistent with previous reports 
(42). Heparin partially reversed the effect of PDS, increasing 
the specific binding of TGF-/3 to the cell monolayer (Fig. 3). 
Addition of  heparin to the binding medium increased specific 
binding in two ways: (a) reducing nonspecific binding (bind- 
ing in the presence of a >100-fold excess of cold competitor) 
to 86% of the level observed in untreated wells (t[13]  =  3.3, 
P  =  0.006); and (b) increasing the total binding of TGF-B to 
21% above untreated wells (t[13]  =  2.74, P  =  0.017). The net 
effect of these two factors is to increase specific binding of 
TGF-~ to cells by 46% above that observed in the absence 
of heparin (t[13]  =  3.3, P  =  0.006). This heparin-stimulated 
binding was not observed in two studies (not shown) in which 
only 1% BSA was used as the binding medium, but was ob- 
served when 10% PDS was used. Heparin-stimulated bind- 
ing is observed when binding is performed either at 4°C, as 
described above, or at 37°C (data not shown) which, com- 
bined with the previous evidence, implies that heparin does 
not affect the levels of the TGF-/3 receptor(s). However, the 
presence of a certain type of receptor may be required be- 
cause saphenous vein SMCs did not show heparin-sensitive 
binding of TGF-~, an effect consistent with our finding that 
anti-TGF-~/does not reverse heparin's  inhibitory effect on 
these cells. 
Effect of  Heparin on the Biological Action of TGF-/3 
The fact that heparin potentiated the specific binding of TGF- 
Figure 5. Effect of  heparin on the electrophoretic mobility of  TGF-/~ 
in serum or plasma, uSI-TGF-/~  in 1% carrier BSA was mixed with 
medium 199 and 10% PDS or 10% whole-blood FBS in the pres- 
ence or absence of 100/~g/ml heparin and electrophoresed in a 1% 
agarose-galactomannan gel under nondenaturing and nonreducing 
conditions. The gel was fixed and then autoradiographically  exposed 
overnight. The arrow indicates the migration of the BSA vehicle as 
determined by Coomassie staining. 
The Journal of Cell Biology,  Volume 109, 1989  444 fl suggested that heparin might also potentiate the biological 
action of TGF-fl. To assess this possibility, the antiprolifera- 
tive effect of TGF-fl was measured in the presence or absence 
of heparin (100 #g/ml). In cells plated in 10% FBS and then 
changed to 5 % PDS, heparin alone had a significant inhibi- 
tory effect on the baseline rate of thymidine incorporation 
(no heparin or TGF-fl [control]  =  7,727 +  447 dpm/well; 
with heparin =  3,581 +  443 dpm/well; mean +  SEM, n  = 
6). To evaluate the heparin/TGF-fl interaction, we expressed 
the effect of each concentration of TGF-fl as a percent inhibi- 
tion relative to its own control or the heparin baseline value 
just mentioned. As Fig. 4 demonstrates, heparin increased 
the inhibitory effect of the lowest tested concentrations of 
TGF-fl without substantially altering the maximal inhibitory 
effect. The inhibitory effect of 50 pg/ml TGF-fl, for instance, 
was increased twofold in the presence of heparin (P < 0.01). 
Thus, at low concentrations of TGF-fl, heparin potentiates its 
antiproliferative effect. 
Effect of Heparin on the TGF-fl/a2-M Complex 
The results of the previous experiments suggested that hepa- 
rin exerts an antiproliferative effect that correlates with its 
ability to potentiate the binding and biological action of TGF- 
fl. Platelet-derived or cell-secreted TGF-fl that is not recep- 
tor bound is rapidly complexed with o~2-M, greatly reduc- 
ing its  biological activity (42).  Other reports  suggest that 
TGF-fl also complexes with fibronectin in plasma (15). We 
examined the possibility that heparin binds to the inactive 
TGF-fl/a2-M  complex in plasma  or serum  and  induces a 
conformational change or dissociation that exposes the ac- 
tive site of TGF-fl to cell surface receptors. 
We  examined  this  hypothesis  by  adding  '2SI-TGF-fl to 
plasma or serum and determining the ability of heparin to mod- 
ify the electrophoretic mobility of the complex. Fig. 5 repre- 
sents the autoradiograph of radiolabeled TGF-fl complexed 
to plasma or serum components and analyzed by nondenatur- 
ing 1% agarose gel electrophoresis. Under these conditions, 
TGF-fl that is either free or is complexed to an uncharged 
protein does not enter the gel, due to its weak cationic nature 
(23).  Migration of TGF-fl into the gel is dependent upon for- 
mation of a complex with a charged protein and is largely 
independent of the molecular weight of the complex. Com- 
plexes formed in the presence of either FBS or PDS appear 
to be modified by the addition of heparin at antiproliferative 
doses as indicated by the increased cathodic migration of the 
radiolabeled TGF-fl (Fig. 5). This suggests that heparin binds 
directly to TGF-fl or to a protein complex containing TGF-fl. 
As shown in Fig. 6, the addition of heparin to ~25I-TGF-fl 
increases the migration of TGF-fl into the gel. This strongly 
suggests that there is a direct interaction between TGF-fl and 
heparin.  However,  the  possibility  remains  that  TGF-fl  is 
complexed to a  trace  contaminant in the albumin carrier 
which is affected by heparin. Also, as shown in Fig. 6, TGF-fl 
forms a complex with purified a2-M. The addition of hepa- 
rin to TGF-fl/a2-M complexes resulted in the enhanced mi- 
gration of a large fraction of the radiolabeled TGF-fl that was 
previously comigrating with c~2-M. When TGF-fl was added 
to fibronectin, we did not observe the same degree of com- 
plex formation that we observed with ot2-M. The addition of 
heparin, however, created the same highly anionic band that 
was observed when heparin was added to TGF-fl alone or in 
Figure 6.  Effect  of heparin on complex formation of '25I-TGF-fl 
with plasma proteins or purified c~2-M. Agarose gel electrophore- 
sis as described for Fig. 5.  ~25I-TGF-/3 in  1%  BSA carrier  was 
mixed with medium 199 and from top to bottom: 100 tLg/ml  heparin, 
100 #g/ml c~2-M(a2M), ot2-M + heparin (a2M 4- Hep), 100 #g/ml 
fibronectin (FN), fibronectin + heparin (FN + Hep), 10% PDS, 
or 10% PDS + heparin (PDS + Hep). Arrow indicates migration 
of purified c~2-M as determined by Coomassie staining. 
combination with a2-M. Densitometric analysis of the Coo- 
massie-stained gel indicated that heparin did not shift the 
u2-M band.  In contrast, fibronectin's mobility was signifi- 
cantly enhanced by heparin,  consistent with previous  re- 
ports (14). However,  in the presence of heparin the radiola- 
beled TGF-fl did not comigrate with fibronectin/heparin com- 
plexes.  These data suggest that heparin binds to TGF-fl and 
thereby dissociates the TGF-fl/a2-M complex. 
As shown in Fig. 7, the dissociation of the TGF-fl/ct2-M 
complex was observed with heparin and dextran sulfate, both 
of which are antiproliferative (33).  RD7, a heparin with low 
anticoagulant  activity  but  some  antiproliferative  activity 
(data not shown), weakly dissociated the TGF-fl/a2-M com- 
plex.  Chondroitin sulfate and dermatan sulfate, which are 
not antiproliferative (17), do not modify TGF-fl/ct2-macro- 
globulin complexes (Fig. 7). To minimize the possible con- 
tribution of any trace contaminants in commercial heparin 
preparations, we used a highly purified heparin to determine 
the  dose-response  characteristics  of this  interaction.  As 
demonstrated in Fig. 8, the dissociation of the TGF-fl/a2-M 
complex by heparin requires  an excess of highly purified 
heparin (HEPL6) as determined by increasing the concen- 
tration of heparin (1 ng/ml to 100/xg/ml) relative to fixed con- 
centrations of '2SI-TGF-fl (20 ng/ml) and et2-M (100/~g/ml). 
As the concentration of heparin is  increased,  the electro- 
phoretic  mobility of ~25I-TGF-fl shows a  marked cathodic 
shift,  while the position  of the  ot2-M on the  Coomassie- 
stained gel was unchanged. Thus, the concentrations of hep- 
arin sufficient to free '25I-TGF-fl from ct2-M are quite simi- 
lar to the antiproliferative concentrations of heparin reported 
by several  laboratories (10, 12,  22, 24,  38, 47). 
Discussion 
TGF-fl is a widely expressed and pluripotent growth factor. 
Platelets contain, and upon activation release, a high molec- 
ular weight, latent form of TGF-fl (67) in quantities sufficient 
McCaffrey et al.  Transforming Growth Factor-fl and Heparin  445 Figure  7.  Specificity of heparin  for the TGF-B/u2-M complex. 
Agarose gel electrophoresis and autoradiography performed as in 
Fig.  5.  Purified o~2-M (a2M) (100 /~g/ml) and  125I-TGF-B were 
mixed with or without 100 t~g/ml  of heparin (Hep), dextran sulfate 
(DS),  chondroitin-6-sulfate (CS),  dermatan  sulfate (DMS),  or 
RD7, a heparin with antiproliferative  but low anticoagulant  activity. 
All polysaccharides were used at 100 #g/ml. 
to generate approximately equimolar concentrations of PDGF 
and TGF-/3 in serum (see reference 57 for review). A variety 
of cell types,  including fibroblasts (25, 29),  macrophages 
(45),  and tumor cell lines (7, 56) produce TGF-/3. Specific, 
high affinity receptors for TGF-/3 have also been observed in 
almost all cell types examined (11, 26, 35, 36, 49,  54, 66). 
The fact that cells can produce levels of TGF-~ to which the 
same cells will respond classifies TGF-~ as a potentially im- 
portant autocrine growth regulator (25).  The biological re- 
sponses to TGF-/3 binding are quite varied:  modulation of 
cellular phenotype (35); and increased synthesis of extracel- 
lular collagen (43, 46,  64,  68),  fibronectin (43,  64,  68), 
thrombospondin (43),  plasminogen activator inhibitor (68), 
and glycosaminoglycans  (3, 5, 13, 46) are observed in several 
cell types including SMC. Increased monocyte chemotaxis 
(65), growth factor production (32, 65), and autoinduction 
of TGF-~'I expression (63) have all been observed after TGF- 
/3 exposure. 
TGF-/3 is a potent growth inhibitor for cultured endothelial 
cells (2,  19, 59)  and B lymphocytes (55).  SMC and fibro- 
blasts are growth stimulated or inhibited depending on the 
particular culture conditions (20, 22, 27, 35).  TGF-/3 is pro- 
duced in an acid-activatable latent form by fibroblasts (30, 
31); and in platelets, TGF-/~ exists in a latent complex with a 
putative precursor polypeptide (39,  67).  While the precise 
activational mechanism is uncertain, it seems likely that the 
complex is proteolytically activated by a  plasmin-like en- 
zyme to form a 26-kD biologically active molecule (34). Ac- 
tive TGF-/3 is rapidly bound to ot2-M (23),  presumably serv- 
ing as a clearance mechanism (9).  Thus, TGF-B may exist 
in two distinct, biologically inactive forms: the original la- 
tent complex with its precursor and a second clearance com- 
plex with tx2-M. 
Although TGF-B  has  not previously been  considered a 
heparin-binding growth factor, our experiments indicate that 
heparin may have important biochemical and physiological 
interactions with this potent growth and metabolic regulator. 
Because heparin is known to interact with acidic fibroblast 
growth factor (aFGF, also known as heparin-binding growth 
factor-l) to potentiate its mitogenic effect on endothelial cells 
(61), an analogous interaction between heparin and TGF-B is 
possible. While it has recently been shown that TGF-/3 binds 
to heparin-Sepharose with greater affinity than does PDGF 
(25, 45),  the physiological significance for this interaction 
was not clear.  Our studies strongly suggest that at least one 
of the growth inhibitory actions of heparin is to potentiate the 
receptor binding and antiproliferative effect of TGF-/~ via 
dissociation of the ct2-M complex. The evidence supporting 
this interaction is derived from several  observations. 
First,  heparin is  a  much less  effective inhibitor of cell 
growth in the absence of serum derived from whole blood, 
which contains both PDGF and TGF-/3 complexed to protein 
macromolecules. Initially this observation seemed to conflict 
with the findings of Reilly and co-workers (47) who reported 
that heparin did inhibit PDGF-stimulated growth. However, 
closer examination of the reported methods indicated that 
5 % calf serum, and thus TGF-/3, was present in the PDGF- 
supplemented medium. Heparin has been reported to inhibit 
SMC  proliferation in  culture conditions using serum  de- 
pleted of PDGF by heparin-Sepharose chromatography (4, 
47). Although these reports have been interpreted as evidence 
that heparin does not interact with a serum factor to cause 
growth inhibition, our results indicate that an interaction be- 
tween o~2-M, which is not removed from serum by heparin- 
Sepharose, and TGF-~, which is only partially removed by 
heparin-Sepharose (25)  and could be supplied by the cul- 
tured cells, is still a plausible mechanism for heparin's an- 
tiproliferative effect in this particular setting. 
The contribution of TOF-/3 to heparin's antiproliferative 
effect is further supported by the fact that in the presence of 
a  neutralizing antibody to TGF-/~, heparin did not inhibit 
SMC proliferation. That TGF-/3 present in serum inhibits 
SMC growth can be strongly inferred from the substantial in- 
crease in DNA synthesis in cells treated with antibody to 
TGF-/3. This "disinhibition" is attributable to the neutraliza- 
tion of TGF-~ present in serum. A similar stimulatory effect 
of anti-TGF-~  is  also  observed  in  serum-free cultures  of 
SMC, suggesting that SMCs produce TGF-~ that regulates 
their own growth. This has not been previously reported for 
Figure 8.  Effect  of increasing heparin concentrations on complex 
formation. Agarose gel electrophoresis as in Figs. 5-7 showing  the 
requirement  of  a  >50-fold molar  excess of purified heparin 
(HepL6) to TGF-/3 (20 ng/ml) is necessary to cause dissociation of 
the t~2-M/1251-TGF-/~  complex, a2-M was present in all lanes at a 
concentration of 100/zg/ml. 
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in an autocrine fashion (25).  The failure of heparin  to in- 
hibit DNA synthesis in the absence of functional TGF-/3 im- 
plies that heparin might facilitate  the interaction  of TGF-B 
with its receptor. 
To test that possibility, it was necessary to examine the cell 
surface binding of TGF-~ in the presence  and  absence  of 
heparin.  At concentrations of TGF-/3 near its apparent dis- 
sociation constant, heparin increased the specific binding of 
TGF-/3 by '~45 % above untreated control wells. Part of this 
effect was to reduce nonspecific binding, suggesting that part 
of TGF-~'s binding to cells is via a heparin-sensitive  site. This 
is consistent with the recent report that the high molecular 
weight receptor for TGF-~ is a glycosaminoglycan and that 
heparinase digestion reduces TGF-/3 binding to the cells by 
'~,20% (54).  Consistent with the increased binding of TGF- 
/3, heparin  also potentiated  the growth inhibitory  action of 
very low concentrations of TGF-/3. Taken together,  it seems 
reasonable to hypothesize that heparin increases the avail- 
ability of TGF-/3 to its receptor,  and thereby  potentiates  the 
antiproliferative  effect of TGF-~ on these cell types. 
One  mechanism  by  which  heparin  could  influence  the 
binding and action of TGF-~ would be for heparin  to bind 
to the TGF-/3 complex that is formed in serum or plasma and 
render  free TGF-~.  It  is has  been  established  that  TGF-~ 
binds to o~2-M in plasma (23) and is less biologically active 
when so bound (42).  Because TGF-~, but not tx2-M, binds 
heparin, we were not surprised to find that the electropho- 
retic mobility of TGF-/3 bound to plasma proteins was sub- 
stantially  altered  by the presence of highly electronegative 
heparin.  This heparin/TGF-~  interaction  exhibited glycos- 
aminoglycan  specificity  and  dose-response  characteristics 
that parallel  those described for heparin's  antiproliferative 
effect. Based on these results, we propose that heparin frees 
TGF-~  from its  binding  site to ~2-M  and  forms a  stable, 
electronegative  complex  that  is  receptor  competent.  The 
large molar excess of heparin necessary to achieve this dis- 
sociation suggests that either a small subtype of heparin  is 
effective or that heparin has a lower affinity  than a2-M  for 
TGF-~. 
An  interaction  between TGF-~ and heparin  would have 
broad physiological  implications because both TGF-/3 and 
heparin-like glycosaminoglycans are produced in substantial 
quantities  by a variety  of cell types.  Endothelial cells,  for 
instance,  produce heparan  sulfate  species  (69),  as  well as 
relatively  high  levels  of latent  TGF-/3, implying  that  the 
combined effect of these factors may help to maintain cell cy- 
cle quiescence  in the  underlying  SMC.  Furthermore,  be- 
cause TGF-/3 is known to increase the synthesis  of matrix 
proteoglycans,  there is the potential for feedforward/feedback 
• mechanisms to regulate  the extracellular activity of TGF-/3 
during wound healing, angiogenesis, and potentially athero- 
genesis. It is interesting  to speculate that a TGF-/3/heparin in- 
teraction  may also be involved in the regulation of bone in- 
tegrity.  Long term heparin therapy is often accompanied by 
osteoporosis (53), and TGF-/3 is already  well recognized as 
having  important  functions in the proliferation and metabo- 
lism of osteoclasts and osteoblasts (6, 44, 60). In conclusion, 
our results suggest the possibility that the interaction of hepa- 
rin, or possibly heparan  sulfate  proteoglycans,  and TGF-/3 
has important regulatory functions in both normal and patho- 
logical conditions of the vasculature.  Further investigation  of 
this interaction will allow a better understanding of the fac- 
tors that govern the balance of growth stimulatory and growth 
inhibitory  signals acting on the mammalian cell. 
This work was supported in part by a grant from the American Federation 
for Aging Research to T. McCaffrey, a National  Institutes of Health (NIH) 
Research Career Development Award (HL01962) to D. Falcone, and NIH 
research grants HL35724  and HL18828  to B.  Weksler. 
Received  for publication  3 November 1988 and in revised form 17 January 
1989. 
References 
1. Assoian, R. K., and M. B. Sporn. 1986. Type/3 transforming growth factor 
in human platelets:  release during  platelet degranulation  and action on 
vascular smooth muscle cells. J.  Cell Biol.  102:1217-1223. 
2. Baird, A., and T. Durkin.  1986. Inhibition of endothelial cell proliferation 
by type ~-transforming growth factor: interactions with acidic and basic 
fibroblast growth  factors.  Biochem.  Biophys.  Res.  Commun.  138:476- 
482. 
3. Bassols, A., and J. Massague.  1986. Transforming  growth factor B regu- 
lates  the  expression  and  structure  of extracellular  matrix  chondroi- 
tin/dermatan  sulfate proteoglycans.  J.  Biol.  Chem.  263:3039-3045. 
4. Benitz, W. E., D. S. Lessler, J. D. Coulson, and M. Bernfield. 1986. Hepa- 
rin inhibits proliferation of fetal vascular smooth muscle cells in the ab- 
sence of platelet derived  growth  factor. J.  Cell.  Physiol.  127:1-7. 
5. Chen, J., H. Hoshi, and W. L. McKeehan. 1987. Transforming growth fac- 
tor type ~ specifically stimulates synthesis of proteoglycan in human adult 
arterial smooth muscle cells. Proc. Natl. Acad. Sci. USA. 84:5287-5291. 
6. Chenu,  C., J.  Pfeilschifter,  G.  R.  Mundy,  and G.  D.  Roodman.  1988. 
Transforming growth factor ~ inhibits formation of osteoclast-like cells 
in  long-term  human  marrow  cultures.  Proc.  Natl.  Acad.  Sci.  USA. 
85:5683-5687. 
7. Clark,  W. C., and J.  Bressler.  1988. Transforming  growth factor-~-like 
activity in tumors of the central nervous system. J. Neurosurg.  68:920- 
924. 
8. Clowes, A., and M. Karnovsky.  1977. Suppression of smooth muscle cell 
proliferation  in injured arteries.  Nature  (Lond.).  265:625-626. 
9. Coffey, R. J., L. J. Kost, R. M. Lyons, H. L. Moses, and N. F. LaRusso. 
1987. Hepatic processing of transforming growth factor B in the rat. J. 
Clin.  Invest.  80:750-757. 
10.  Del Vecchio, P. J., R. Bizios, L. A. Holleran, T. K. Judge, and G. L. Pinto. 
1988. Inhibition of human scleral fibroblast proliferation  with heparin. 
Invest.  Ophthalmol.  &  Visual Sci.  29:1272-1276. 
11.  Ewton,  D. Z., G. Spizz, E. N. Olson, and J.  R. Florini.  1988. Decrease 
in transforming growth factor-~ binding and action during differentiation 
in muscle cells. J.  Biol.  Chem.  263:4029-4032. 
12.  Fager, G., G. K. Hansson, P. Ottosson, B. Dahllof, and G. Bondjers. 1988. 
Human arterial smooth muscle cells in culture: effects of platelet-derived 
growth  factor  and  heparin  on  growth  in  vitro.  Exp.  Cell  Res. 
176:319-335. 
13.  Falanga, V., S. L. Tiegs, S. P. Alstadt, A. B. Roberts, and M. B. Sporn. 
1987. Transforming growth factor-beta: selective increase in glycosamino- 
glycan synthesis by cultures of fibroblasts from patients with progressive 
systemic sclerosis. J.  Invest.  DermatoL  89:100-104. 
14.  Falcone,  D. J., and B. G. Salisbury.  1988. Fibronectin stimulates macro- 
phage uptake of low density lipoprotein-heparin-collagen complexes. Ar- 
teriosclerosis.  8:263-273. 
15.  Fava, R. A., and D. B. McClure.  1987. Fibronectin-associated transform- 
ing growth factor. J.  Cell.  Physiol.  131 : 184-189. 
16.  Fritze, L., C. F. ReiUy, and R. D. Rosenberg.  1985. An antiproliferative 
heparan sulfate species produced by postconfluent smooth muscle cells. 
J.  Cell.  Biol.  100:1041-1049. 
17.  Guyton, J., R. Rosenberg, A. Clowes, and M. Karnovsky.  1980. Inhibition 
of rat  arterial  smooth muscle cell proliferation  by heparin.  I.  In vivo 
studies  with  anticoagulant  and  non-anticoagulant  heparin.  Circ.  Res. 
46:625-634. 
18.  Deleted in proof. 
19.  Heimark, R. L., D. R. Twardizik,  and S. M. Schwartz.  1986. Inhibition 
of  endothelial regeneration by type-beta transforming growth factor from 
platelets.  Science (Wash.  DC).  233:1078-1080. 
20.  Hill,  D. J., A. J. Strain,  S. F. Elstow,  I. Swenne, and R. D. G. Milner. 
1986. Bi-functional action of transforming growth factor-/3 on DNA syn- 
thesis  in early  passage human fetal fibroblasts.  J.  Cell.  Physiol.  128: 
322-328. 
21. Hoover, R., R. Rosenberg, W. Haering, and M. Karnovsky.  1980. Inhibi- 
tion of rat smooth muscle cell proliferation by heparin II. In vitro studies. 
Circ.  Res. 47:578-583. 
22.  Hoshi, H., M. Kan, J. K. Chen, and W. L. McKeehan. 1988. Comparative 
endocrinology-paracrinology-autocrino',ogy of human adult large vessel 
endothelial  and  smooth  muscle  cells.  In  Vitro  Cell.  &  Dev.  Biol. 
McCaffrey et al.  Transforming  Growth Factor-f3 and Heparin  447 24:309-320. 
23. Huang, S., P. O'Grady, and J. Huang. 1988. Human transforming growth 
factor-beta/alpha-2-macroglobulin  complex is a latent form of transform- 
ing growth factor-beta.  J.  BioL  Chem. 263:1535-1541. 
24. Kardami, E.,  D.  Spector,  and R.  C.  Strohman.  1988.  Heparin inhibits 
skeletal  muscle growth in vitro. Dev.  Biol. 126:19-28. 
25. Keski-Oja, J., R. M. Lyons, and H. L. Moses. 1987. lmmunodetection  and 
modulation of cellular growth with antibodies against native transforming 
growth factor-El.  Cancer Res. 47:6451-6458. 
26. Kimchi, A., X. F. Wang, R. A. Weinberg, S. Cheifetz, and J. Massague. 
1988.  Absence of TGF-/3 receptors and growth inhibitory  responses in 
retinoblastoma cells. Science  (Wash. DC). 240:196-198. 
27. Kimura, A., O. Katoh, and A. Kuramoto. 1988. Effects of platelet derived 
growth factor, epidermal growth factor and transforming growth factor-/3 
on the growth of human marrow fibroblasts.  Br. J. Haematol. 69:9-12. 
28. Klebe, R. J., L. V. Escobedo, K. L. Bentley, and L. K. Thompson. 1986. 
Regulation of cell motility, morphology, and growth by sulfated glycos- 
aminoglycans. Cell Motil.  Cytoskeleton. 6:273-28t. 
29. Kryceve-Martinerie, C., D. A. Lawrence, J. Crochet, P. Jullien, and P. 
Vigier.  1985. Further study of/3-TGFs released by virally transformed 
and non-transformed cells. Int. J.  Cancer. 35:553-558. 
30. Lawrence, D. A., R. Pircher, and P. Jullien.  1985.  Conversion of a high 
molecular weight latent #-TGF from chicken embryo fibroblasts into a 
low molecular weight active/~-TGF under acidic conditions. Biochem. 
Biophys.  Res.  Commun.  133:1026-1034. 
31. Lawrence, D. A., R. Pitcher, C. Kryceve-Martineri, and P. Jullien. 1984. 
Normal embryo fibroblasts release transforming  growth factors in a latent 
form. J.  Cell. Physiol. 121:184-188. 
32. Leof, E. B., J. A. Proper, A. S. Goustin, G. D. Shipley, P. E. DiCorleto, 
and H. L. Moses. 1986.  Induction of c-sis mRNA and activity similar 
to platelet-derived  growth factor by transforming growth factor/3:  a pro- 
posed model for indirect mitogenesis involving autocrine activity. Proc. 
Natl. Acad. Sci. USA. 83:2453-2457. 
33. Lippman, M. M., and M. B. Mathews. 1977. Heparins: varying effects on 
cell proliferation  in vitro and lack of correlation with anticoagulant activ- 
ity.  Fed. Proc.  36:55-59. 
34. Lyons, R. M., J. Keski-Oja, and H. L. Moses. 1988. Proteolytic  activation 
of  latent  transforming  growth  factor-B  from  fibroblast-conditioned 
medium. J.  Cell Biol. 106:1659-1665. 
35. Majack, R. A.  1987.  Beta-type  transforming growth factor specifies  or- 
ganizational behavior in vascular smooth muscle cell  cultures. J.  Cell 
Biol.  105:465-471. 
36. Massague, J., and B. Like. 1985. Cellular receptors for type/3 transforming 
growth factor.  J.  Biol. Chem. 260:2636-2645. 
37. McCaffrey, T.  A.,  L.  A.  Agarwal, and B.  B,  Weksler.  1988.  A  rapid 
fluorometric  DNA assay for the measurement  of cell density and prolifer- 
ation in vitro. In  Vitro Cell.  & Dev.  Biol. 24:247-252. 
38. McCaffrey, T. A., A. C. Nicholson, P. E. Szabo, M. E. Weksler, and B. B. 
Weksler. 1988. Aging and arteriosclerosis: the increased proliferation of 
arterial smooth muscle cells isolated  from old rats is associated with in- 
creased platelet-derived  growth factor-like  activity. J.  Exp. Med. 167: 
163-174. 
39. Miyazono, K., U. Hellman, C. Wernstedt, and C. Heldin.  1988.  Latent 
high molecular weight complex of transforming growth factor-beta 1. J. 
Biol.  Chem. 263:6407-6415. 
40. Nilsson, J., T. Ksiazek, C. H. Heldin, and J. Tfiyberg. 1983. Demonstra- 
tion of stimulatory effects of platelet-derived  growth factor on cultivated 
rat arterial  smooth muscle cells. Exp. Cell Res.  145:231-237. 
41. Nilsson, J., T. Ksiazek, J. Thyberg, and A. Wasteson. 1983. Cell surface 
components and growth regulation in cultivated arterial  smooth muscle 
cells. J.  Cell Sci. 64:107-121. 
42. O'Connor-McCourt, M. D., and L. M. Wakefield. 1987, Latent transform- 
ing growth factor-# in serum. J.  Biol. Chem. 262:14090-14099. 
43. Penttinen, R.  P.,  S.  Kobayashi, and P.  Bornstein.  1988.  Transforming 
growth factor/3 increases mRNA for matrix proteins both in the presence 
and in the absence of changes in mRNA stability. Proc. Natl. Acad. Sci. 
USA. 85:1105-1108. 
44. Pfeilschifler, J., S.  M. Seyedin, and G. R. Mundy.  1988.  Transforming 
growth factor beta inhibits bone resorption in fetal rat lung bone cultures. 
J.  Clin. Invest. 82:680-685. 
45. Rappolee, D. A., D. Mark, M. J. Banda, and Z. Werb. 1988. Wound mac- 
rophages express TGF-u and other growth factors in vivo: analysis by 
mRNA phenotyping. Science  (Wash. DC). 241:708-712. 
46. Redini, F., P. Galera, A. Mauviel, G, Loyau, andJ. P. Pujol.  1988. Trans- 
forming growth factor ~ stimulates collagen and glycosaminoglycan  bio- 
synthesis in cultured rabbit articular chondrocytes. FEBS (Fed. Eur. Bio- 
chem.  Soc.) Lett. 234:172-176. 
47. Reilly, C. F., L. Fritze, and R. D. Rosenberg.  1986.  Heparin inhibition 
of smooth muscle cell proliferation:  a cellular site of action. J. Cell. Phys- 
iol.  129:11-19. 
48. Reilly, C. F., L. M. S. Fritze, and R. D. Rosenberg. 1987. Antiprolifera- 
tive effects of heparin on vascular smooth muscle cells are reversed by 
epidermal growth factor. J.  Cell. Physiol. 131:149-157. 
49. Rizzino, A. 1987.  Appearance of high affinity receptors for type/3 trans- 
forming growth factor during differentiation  of murine embryonal carci- 
noma cells. Cancer Res.  47:4386-4390. 
50. Ross, R.  1985.  Platelets and atherosclerosis. In Interactions of Platelets 
with the Vessel Wall. J. Oates, J. Hawiger, and R. Ross, editors. Ameri- 
can Physiological Society, Bethesda, MD.  I I I-116. 
51. Ross, R., A. Faggiotto, D. Bowen-Pope, and E. Raines. 1984.  The role 
of endothelial injury and platelet and macrophage interactions in athero- 
sclerosis. Circulation. 70:77-82. 
52. Ruff, E., and A. Rizzino.  1986.  Preparation and binding of radioactively 
labeled  porcine transforming growth factor type B. Biochem.  Biophys. 
Res.  Commun.  138:714-719. 
53. Sackler, J., and L. Lui. 1973. Heparin-induced osteoporosis. Br. J. Radiol. 
46:548-550. 
54. Segarini, P.  R.,  and S.  M.  Seyedin.  1988.  The high molecular weight 
receptor to transforming growth factor-B  contains glycosaminoglyean 
chains. J.  Biol. Chem. 263:8366-8370. 
55. Smeland, E. B., H. K. Blomboff, H. Holte, E. Ruud, K. Beiske, S. Fun- 
derud, T. Godal, and R. Ohlsson. 1987. Transforming  growth factor type 
(TGF/3) inhibits G~ to S transition, but not activation of human B lym- 
phocytes. Exp. Cell Res.  171:213-222. 
56. Soderdahl, G., C. Betsholtz, A. Johansson, K. Nilsson, andJ. Bergh. 1988. 
Differential  expression of platelet-derived  growth factor and transform- 
ing growth factor genes in small- and non-small-cell human lung carci- 
noma lines. Int. J.  Cancer. 41:636-641. 
57. Sporn, M. B., A. B. Roberts, L. M. Wakefield, and B. de Crombrugghe. 
1987. Some recent advances in the chemistry and biology of transforming 
growth factor-beta.  J.  Cell Biol. 105:1039-1045. 
58. Stemerman, M. B., R. Weinstein, J. W. Rowe, T. Macing, R. Fuhro, and 
R. Gardner.  1982. Vascular smooth muscle cell growth kinetics in vivo 
in aged rats. Proc. Natl. Acad.  Sci. USA. 79:3863-3866. 
59. Takehara, K., E. C. LeRoy, and G. R. Grotendorst.  1987. TGF-B inhibi- 
tion of endothelial cell proliferation:  alteration of EGF binding and EGF- 
induced  growth-regulatory  (competence)  gene  expression.  Cell. 49: 
415-422. 
60. Tashjian, A. H., E. F. Voelkel, M. Lazzaro, F. R. Singer, A. B. Roberts, 
R. Derynck, M. E. Winkler, and L. Lcvine. 1985. ct and/3 human trans- 
forming growth  factors stimulate prostaglandin production and bone 
resorption  in  cultured  mouse calvaria.  Proc.  Natl. Acad. Sci. USA. 
82:4535-4538. 
61. Thornton, S., S. Mueller, and E. Levine. 1983. Human endothelial cells: 
use of heparin in cloning and long-term serial cultivation. Science (Wash. 
DC). 222:623-625. 
62. Tsukada, T., M. A. McNutt, R. Ross, and A. M. Gown.  1987.  HHF35, 
a muscle actin-specific  monoclonal antibody. II.  Reactivity  in normal, 
reactive, and neoplastic human tissues. Am. J.  Pathol.  127:389--401. 
63. Van Obberghen-Schilling, E., N. S. Roche, K. C. Flanders, M. B. Sporn, 
and A. B. Roberts. 1988. Transforming  growth factor BI positively regu- 
lates its own expression in normal and transformed cells. J. Biol. Chem. 
263:7741-7746. 
64. Varga, J., J. Rosenbloom, and S. A. Jimenez. 1987. Transforming growth 
factor/3 (TGFB) causes a persistent increase in steady-state amounts of 
type I and type IIl collagen and fibronectin  mRNAs in normal human  der- 
mal fibroblasts.  Biochem. J.  247:597-604. 
65. Wahl, S. M., D. A. Hunt, L. M. Wakefield, N. McCartney-Francis, L.  M. 
Wahl, A. B. Roberts, and M. B. Sporn. 1987. Transforming  growth fac- 
tor type ~ induces monocyte chemotaxis and growth factor production. 
Proc.  Natl. Acad. Sci. USA. 84:5788-5792. 
66. Wakefield, L. M., D. M. Smith, T. Masui, C. C. Harris, and M. B. Sporn. 
1987. Distribution and modulation of the cellular receptor for transform- 
ing growth factor-beta, J.  Cell Biol. 105:965-975. 
67. Wakefield, L. M., D. M. Smith, K. C. Flanders, and M. B. Sporn.  1988. 
Latent  transforming growth  factor-B  from  human platelets.  J.  Biol. 
Chem. 263:7646-7654. 
68. Wrana, J. L., M. Maeno, B. Hawrylyshyn, K. L. Yao, C. Domenicucci, 
and J. Sodek.  1988. Differential  effects of transforming growth factor-B 
on the synthesis  of  extracellular matrix proteins by normal fetal rat calvar- 
ial bone cell  populations. J.  Cell Biol. 106:915-924. 
69. Yahalom, J., A. EIdor,  Z. Fuks, and I. VIodavsky. 1984.  Degradation of 
sulfated proteoglycans in the subendothelial extracellular matrix by hu- 
man platelet  heparitinase. J.  Clin. Invest. 74:1842-1849. 
The Journal of Cell  Biology, Volume 109,  1989  448 